Capital One Initiates Coverage On CARISMA Therapeutics with Overweight Rating, Announces Price Target of $10
Portfolio Pulse from Benzinga Newsdesk
Capital One analyst Naureen Quibria has initiated coverage on CARISMA Therapeutics (NASDAQ:CARM) with an Overweight rating and a price target of $10.
October 03, 2023 | 2:17 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Capital One has initiated coverage on CARISMA Therapeutics with an Overweight rating and a price target of $10.
The initiation of coverage by Capital One with an Overweight rating indicates a positive outlook for CARISMA Therapeutics. The price target of $10 also suggests potential upside, which could positively impact the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100